First, for proteins, when applying the commonly used clinical cutoff of 35 U/mL for CA125 alone, the observed sensitivity was 76.2% for overall ovarian cancer and 65.2% for early-stage ovarian cancer, a performance consistent with clinical reports. The gene discussed is MUC16; the disease is ovarian cancer.